RankAlpha logo
Back to Rankings

SNDX

SyndaxC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case is that SNDX has crossed from story stock to commercial oncology company: two approved products generated more than $275M of 2025 product sales, sequential launch growth remained strong into 4Q25, and management is signaling a path to profitability if operating expenses stay stable [#8-K-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +12.2.
What can break
Frontline AML studies for revumenib take longer, enroll slower, or produce weaker-than-expected efficacy or safety.
Momentum
17
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $29.00 · Bull $36.00 · Bear $16.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $39.30
Why
Momentum17 · Δ7d +1.8
Value41 · Δ7d +0.1
Sentiment100 · Δ7d +12.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
17
34% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
+2.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+12.2
Δ21d
+27.7
Why this grade

Composite grade C. Momentum 16.8 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.67B
Beta
0.46
Shares Out
86.91M
P/E (TTM) · Derived
-5.8
P/S (TTM)
15.75
P/FCF (TTM) · Derived
-5.34
Rev YoY
+267.0%
EPS YoY
+28.8%
Gross Margin
+95.4%
Op Margin
-275.1%
Net Debt
-$239.22M
Current Ratio
4.64
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology